Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age4-75
SponsorBristol-Myers Squibb
About this trial
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.
Disqualifiers
Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.
Trial design
Design model
Single group
Treatments tested in this trial
Deucravacitinib
DrugSpecified dose on specified days
Treatment groups
2,300 Participants
are divided into 1 treatment groupGroup A: Deucravacitinib ArmExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of participants treated
Time frame
Up to approximately 28 days after last dose of deucravacitinibLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: